Colorectal cancer prognosis: is it all mutation, mutation, mutation?

被引：11

作者：

Hassan, AB ^{[1
]}

Paraskeva, C

机构：

[1] Univ Bristol, Sch Med Sci, Dept Cellular & Mol Med, Bristol BS8 1TD, Avon, England

[2] Univ Bristol, Sch Med Sci, Dept Pathol & Microbiol, Bristol BS8 1TD, Avon, England

来源：

GUT | 2005年 / 54卷 / 09期

关键词：

D O I：

10.1136/gut.2005.070946

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

For the 500 000 new cases of colorectal cancer in the world each year, identification of patients with a worse prognosis and those who are more likely to respond to treatment is a challenge. There is an increasing body of evidence correlating genetic mutations with outcome in tumours derived from human colorectal cancer cohorts. K-ras, but not p53 or APC, mutations appear to be associated with poorer overall survival in colorectal cancer patients.

引用

页码：1209 / 1211

页数：3

共 22 条

[1] Kirsten ras mutations in patients with colorectal cancer:: the 'RASCAL II' study [J].

Andreyev, HJN ;

Norman, AR ;

Cunningham, D ;

Oates, J ;

Dix, BR ;

Iacopetta, BJ ;

Young, J ;

Walsh, T ;

Ward, R ;

Hawkins, N ;

Beranek, M ;

Jandik, P ;

Benamouzig, R ;

Jullian, E ;

Laurent-Puig, P ;

Olschwang, S ;

Muller, O ;

Hoffmann, I ;

Rabes, HM ;

Zietz, C ;

Troungos, C ;

Valavanis, C ;

Yuen, ST ;

Ho, JWC ;

Croke, CT ;

O'Donoghue, DP ;

Giaretti, W ;

Rapallo, A ;

Russo, A ;

Bazan, V ;

Tanaka, M ;

Omura, K ;

Azuma, T ;

Ohkusa, T ;

Fujimori, T ;

Ono, Y ;

Pauly, M ;

Faber, C ;

Glaesener, R ;

de Goeij, AFPM ;

Arends, JW ;

Andersen, SN ;

Lövig, T ;

Breivik, J ;

Gaudernack, G ;

Clausen, OPF ;

De Angelis, P ;

Meling, GI ;

Rognum, TO ;

Smith, R .

BRITISH JOURNAL OF CANCER, 2001, 85 (05) :692-696

[2] The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma [J].

Conlin, A ;

Smith, G ;

Carey, FA ;

Wolf, CR ;

Steele, RJC .

GUT, 2005, 54 (09) :1283-1286

[3] Explaining variation in familial adenomatous polyposis: relationship between genotype and phenotype and evidence for modifier genes [J].

Crabtree, MD ;

Tomlinson, IPM ;

Hodgson, SV ;

Neale, K ;

Phillips, RKS ;

Houlston, RS .

GUT, 2002, 51 (03) :420-423

[4] Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer [J].

Cunningham, D ;

Humblet, Y ;

Siena, S ;

Khayat, D ;

Bleiberg, H ;

Santoro, A ;

Bets, D ;

Mueser, M ;

Harstrick, A ;

Verslype, C ;

Chau, I ;

Van Cutsem, E .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (04) :337-345

[5] Genetic predisposition to colorectal cancer [J].

de la Chapelle, A .

NATURE REVIEWS CANCER, 2004, 4 (10) :769-780

[6] Genetic tumor markers with prognostic impact in Dukes' stages B and C colorectal cancer patients [J].

Diep, CB ;

Thorstensen, L ;

Meling, GI ;

Skovlund, E ;

Rognum, TO ;

Lothe, RA .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (05) :820-829

[7] Mutations and allelic loss of p53 in primary tumor DNA from potentially cured patients with colorectal carcinoma [J].

Forslund, A ;

Lönnroth, C ;

Andersson, M ;

Brevinge, H ;

Lundholm, K .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (11) :2829-2836

[8] Heterogeneity studies identify a subset of sporadic colorectal cancers without evidence for chromosomal or microsatellite instability [J].

Georgiades, IB ;

Curtis, LJ ;

Morris, RM ;

Bird, CC ;

Wyllie, AH .

ONCOGENE, 1999, 18 (56) :7933-7940

[9] The hallmarks of cancer [J].

Hanahan, D ;

Weinberg, RA .

CELL, 2000, 100 (01) :57-70

[10] Microsatellite-stable diploid carcinoma: a biologically distinct and aggressive subset of sporadic colorectal cancer [J].

Hawkins, NJ ;

Tomlinson, I ;

Meagher, A ;

Ward, RL .

BRITISH JOURNAL OF CANCER, 2001, 84 (02) :232-236

← 1 2 3 →